Fig. 4: Cysteamine decreases the production of SARS-CoV-2 variants in Calu-3 cells. | Cell Death Discovery

Fig. 4: Cysteamine decreases the production of SARS-CoV-2 variants in Calu-3 cells.

From: Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants

Fig. 4: Cysteamine decreases the production of SARS-CoV-2 variants in Calu-3 cells.

(A, B) Calu-3 cells were treated with cysteamine (1000 µM) or H2O (1% v/v) 1 h before SARS-CoV-2 infection (MOI = 0.01) as indicated. (A) Virus yield of culture media from SARS-CoV-2-infected cells was measured by back-titration as described in the methods. Infectious titers were calculated with the Reed–Muench method and expressed as 50% tissue-culture effective dose (TCID50) values. (B) The efficacy of the cysteamine treatment in Calu-3 cells was expressed as percentage of inhibition of the virus yields measured in panel A. Statistical analysis was performed using Wilcoxon matched-pairs rank test. Data are expressed as median ± S.D. (n = 9) of three independent experiments performed in triplicate.

Back to article page